Compare FMC Corp (FMC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Tango Therapeutics Inc. — how do they compare? FMC Corp trades at $8.05 (market cap $1.29B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 2.9× FMC Corp's market cap, and FMC Corp pays a 3.85% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and Tango Therapeutics Inc. for 0 Days on average.
| FMC | TNGX | |
|---|---|---|
Market Cap | $1.29B | $3.75B |
Volume | 3,528,603 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $32.90 |
52-Week Low | $8.09 | $7.50 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | $5.10B | $2.77B |
Dividend Yield | 3.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.09, down 2.76% on the day, with a bearish technical signal and weak fundamentals including a net income margin of -84.83% and negative ROE of -91.47% for 2025. Recent earnings show mixed results with Q2 2026 beating estimates, but revenue has declined from $5.8B in 2022 to $3.47B in 2025. Positive developments include a regulatory filing for rimisoxafen in Brazil and a minority equity investment by Tessenderlo Group, yet cash flow from operations remains negative.
The outlook is cautious; while analyst consensus is a buy with a $14.20 price target, high debt and cyclical industry headwinds pose significant risks. Aggressive deleveraging efforts may improve financial stability, but persistent revenue declines and negative profitability underscore substantial challenges for near-term recovery.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
